Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: Dose-response effectiveness and extended safety testing in rhesus monkeys

Journal of Virology

Volumn 74, Issue 4, 2000, Pages 1742-1751

  Monath, T P ^a   Levenbook, I ^b   Soike, K ^c   Zhang, Z X ^a   Ratterree, M ^c   Draper, K ^d   Barrett, A D T ^e   Nichols, R ^a   Weltzin, R ^a   Arroyo, J ^a   Guirakhoo, F ^a  

^a Acambis   (United States)

^b Tulane Regional Primate Center ^*  (United States)

^c TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^d CHARLES RIVER LABORATORIES   (United States)

^e University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JAPANESE ENCEPHALITIS VACCINE; YELLOW FEVER VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ENCEPHALITIS; EPIDEMIC ENCEPHALITIS; IMMUNOGENICITY; JAPANESE ENCEPHALITIS VIRUS; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; VACCINATION; VIREMIA; YELLOW FEVER; YELLOW FEVER FLAVIVIRUS;

ANIMALS; CONSUMER PRODUCT SAFETY; ENCEPHALITIS VIRUS, JAPANESE; ENCEPHALITIS, JAPANESE; FEMALE; GENETIC VECTORS; HUMANS; INJECTIONS, SUBCUTANEOUS; MACACA MULATTA; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED ICR; NEUTRALIZATION TESTS; RECOMBINATION, GENETIC; VACCINES, ATTENUATED; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES; VIREMIA; VIRULENCE; YELLOW FEVER VIRUS;

EID: 0033947590     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.4.1742-1751.2000     Document Type: Article

References (38)

1. Aihara, S., C. M. Rao, and Y. X. Yu. 1991. Identification of mutations that occurred on the genome of Japanese encephalitis virus during the attenuation process. Virus Genes 5:95-109.
2. Chambers, T. J., T. F. Tsai, Y. Pervikov, and T. P. Monath. 1997. Vaccine development against dengue and Japanese encephalitis: report of a World Health Organization meeting. Vaccine 15:1494-1502.
3. Chambers, T. J., A. Nestorowicz, P. W. Mason, K. H. Eckels, and C. M. Rice. 1999. Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J. Virol. 73:3095-3101.
4. Chen, W. R., R. B. Tesh, and R. Rico-Hesse. 1990 Genetic variation of Japanese encephalitis virus in nature. J. Gen. Virol. 71:2915-2920.
5. Chen, W. R., R. Rico-Hesse, and R. B. Tesh. 1992. A new genotype of Japanese encephalitis from Indonesia. Am. J. Trop. Med. Hyg. 47:61-69.
6. Chung, Y. J., J. H. Nam, S. J. Ban, and H. W. Cho. 1996. Antigenic and genetic analysis of Japanese encephalitis viruses isolated from Korea. Am. J. Trop. Med. Hyg. 55:91-97.
7. Edelman, R., A. Nisalak, A. Pariyanonda, S. Udomsakdi, and D. O. Johnsen. 1973. Immunoglobulin response and viremia in dengue-vaccinated gibbons repeatedly challenged with Japanese encephalitis virus. Am. J. Epidemiol. 97:208-218.
8. Goverdhan, M. K., A. B. Kulkarni, A. K. Gupta, C. D. Tupe, and J. J. Rodrigues. 1992. Two-way cross-protection between West Nile and Japanese encephalitis viruses in bonnet macaques. Acta Virol. 36:277-283.
9. Guirakhoo, F., Z. Zhang, T. J. Chambers, S. Delagrave, J. Arroyo, A. D. T. Barrett, and T. P. Monath. 1999. Immunogenicity, genetic stability and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (Chimerivax™-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology 257:363-372.
10. Harrington, D. G., D. E. Hilmas, M. R. Elwell, R. E. Whitmire, and E. L. Stephen. 1977. Intranasal infection of monkeys with Japanese encephalitis virus: clinical response and treatment with a nuclease-resistant derivative of poly(I)-poly(C). Am. J. Trop. Med. Hyg. 26:1191-1198.
11. Hoke, C. H., A. Nisalak, N. Sangawhipa, S. Jatanasen, T. Laorakapongse, B. L. Innis, S. Kotchasenee, J. B. Gingrich, J. Latendresse, K. Fukai, and D. S. Burke. 1988. Protection against Japanese encephalitis by inactivated vaccines. N. Engl. J. Med. 319:608-614.
12. Kayser, M., H. Klein, and I. Paasch. 1985. Human antibody response to immunization with 17D yellow fever and inactivated TBE vaccine. J. Med. Virol. 17:35-44.
13. Konishi, E., M. Yamaoka, Khin-Sane-Win, I. Kurane, and P. W. Mason. 1998. Induction of protective immunity against Japanese encephalitis with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes. J. Virol. 72:4925-4930.
14. Konishi, E., M. Yamaoka, Kin-Sane-Win, I. Kurane, K. Takada, and P. W. Mason. 1999. The anamnestic neutralizing antibody response is critical for protection of mice from challenge following vaccination with a plasmid encoding the Japanese encephalitis virus premembrane and envelope genes. J. Virol. 73:5527-5534.
15. Lee, H. W., and W. F. Scherer. 1961. The anamnestic antibody response to Japanese encephalitis virus in monkeys and its implications concerning naturally acquired immunity in man. J. Immunol. 86:151-164.
16. Levenbook, I. S., L. J. Pelleu, and B. L. Elisberg. 1987. The monkey safety test for neurovirulence of yellow fever vaccines: the utility of quantitative clinical evaluation and historical examination. J. Biol. Stand. 15:305-313.
17. Lubiniecki, A. S., R. H. Cypess, and W. M. Hammon. 1973. Passive immunity for arbovirus infection. Am. J. Trop. Med. Hyg. 22:535-542.
18. Monath, T. P. 1999. Yellow fever, p. 815-879. In S. Plotkin and W. Orenstein (ed.), Vaccines. W. B. Saunders and Company, Philadelphia, Pa.
19. Monath, T. P., C. B. Cropp, and A. K. Harrison. 1983. Mode of entry of a neurotropic arbovirus into the central nervous system: reinvestigation of an old controversy. Lab. Investig. 48:399-410.
20. Monath, T. P., K. Soike, I. Levenbook, Z.-X. Zhang, J. Arroyo, S. Delagrave, G. Myers, A. D. T. Barrett, R. E. Shope, T. J. Chambers, and F. Guirakhoo. 1999. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax™) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. Vaccine 17:1869-1882.
21. Morris, J. A., J. R. Connor, and J. E. Smadel. 1955. Infection and immunity patterns in monkeys injected with viruses of Russian spring-summer and Japanese encephalitis. Am. J. Hyg. 62:327-341.
22. National Institutes of Health. 1985. Guide for the care and use of laboratory animals, rev. ed. Department of Health and Human Services publication no. (NIH) 85-23. National Institutes of Health, Bethesda, Md.
23. Ni, H., and A. D. T. Barrett. 1998. Attenuation of Japanese encephalitis virus by selection of its mouse brain membrane receptor preparation escape variants. Virology 241:30-36.
24. Ni, H., N. J. Burns, G.-J. Chang, M.-J. Zhang, M. R. Wills, D. W. Trent, P. G. Sanders, and A. D. T. Barrett. 1994. Comparison of nucleotide and deduced amino acid sequence of the 5′ non-coding region and structural protein genes of the wild-type Japanese encephalitis virus strain SA14 and its attenuated vaccine derivatives. J. Gen. Virol. 75:1505-1510.
25. Ni, H., G.-J. Chang, H. Xie, D. W. Trent, and A. D. T. Barrett. 1995. Molecular basis of attenuation of neurovirulence of wild-type Japanese encephalitis virus strain SA14. J. Gen. Virol. 76:409-413.
26. Nitayaphan, S., J. G. Grant, G.-J. Chang, and D. W. Trent. 1990. Nucleotide sequence of virulent SA14 strain of Japanese encephalitis and its attenuated derivative. Virology 177:541-552.
27. Rey, F. A., F. X. Heinz, C. Mandl, C. Kunz, and S. C. Harrison. 1995. The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Science 375:291-195.
28. Raengsakulrach, B., A. Nisalak, M. Gettayacamin, V. Thirawuth, G. D. Young, K. S. A. Myint, L. M. Ferguson, C. H. Hoke, Jr., B. L. Innis, and D. W. Vaughn. 1999. An intranasal challenge model for testing Japanese encephalitis vaccines in rhesus monkeys. Am. J. Trop. Med. Hyg. 60:329-337.
29. Ritchie, S. A., D. Phillips, A. Broom, J. Mackenzie, M. Poidinger, and A. van den Hurk. 1997. Isolation of Japanese encephalitis virus from Culex annulirostris in Australia. Am. J. Trop. Med. Hyg. 56:80-84.
30. Rozensweig, E. C., R. W. Babione, and C. L. Wisseman, Jr. 1963. Immunological studies with group B arthropod-borne viruses. Am. J. Trop. Med. Hyg. 12:232-241.
31. Smithburn, K. C. 1956. Immunology of yellow fever, p. 11-27. In K. C. Smithburn et al. (ed.), Yellow fever vaccination. World Health Organization, Geneva, Switzerland.
32. Smithburn, K. C. and A. F. Mahaffy. 1945. Immunization against yellow fever. Am. J. Trop. Med. 45:217-226.
33. Sumiyoshi, H., G. H. Tignor, and R. E. Shope. 1995. Characterization of a highly attenuated Japanese encephalitis virus generated from molecularly cloned cDNA. J. Infect. Dis. 171:1144-1151.
34. Tsai, T. F., G.-J. J. Chang, and Y.-X. Yu. 1999. Japanese encephalitis vaccines, p. 672-710. In S. Plotkin and W. Orenstein (ed.), Vaccines. W. B. Saunders and Company, Philadelphia, Pa.
35. Wills, M. R., B. K. Sil, T. X. Lao, and A. D. T. Barrett. 1992. Antigenic characterization of the live attenuated Japanese encephalitis virus SA14-14-2: a comparison with isolates of virus covering a wide geographic area. Vaccine 10:861-872.
36. World Health Organization. 1998. Requirements for yellow fever vaccine (Requirements for Biological Substances no. 3, revised 1495). WHO Tech. Rep. Ser. 872:31-68.
37. Yu, Y.-X., P. F. Wu, J. Ao, L. H. Liu, and H. M. Lim. 1981. Selection of a better immunogenic and highly attenuated live vaccine virus strain of JE. I. Some biological characteristics of SA14-14-2 mutant. Chin. J. Microbiol. Immunol. 1:77-84.
38. Zhang, M., M. Wang, S. Jiang, and W. Ma. 1989. Passive protection of mice, goats, and monkeys against Japanese encephalitis with monoclonal antibodies. J. Med. Virol. 29:133-138.